Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Downgraded by Wall Street Zen to “Buy”

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

KNSA has been the topic of a number of other research reports. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Citigroup lifted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, June 29th. Finally, Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $62.71.

Kiniksa Pharmaceuticals International Stock Down 3.0%

Shares of KNSA stock traded down $1.94 during trading hours on Friday, hitting $63.44. 443,134 shares of the company’s stock traded hands, compared to its average volume of 1,012,453. The stock’s 50 day simple moving average is $55.92 and its 200 day simple moving average is $48.53. The stock has a market cap of $4.88 billion, a PE ratio of 70.49 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 12 month low of $26.27 and a 12 month high of $67.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 earnings per share. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares of the company’s stock, valued at approximately $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the transaction, the director owned 12,546 shares in the company, valued at $628,554.60. The trade was a 51.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 628,427 shares of company stock valued at $32,833,228 over the last 90 days. Company insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP grew its holdings in Kiniksa Pharmaceuticals International by 2.3% in the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after purchasing an additional 90,194 shares during the period. Vanguard Group Inc. boosted its position in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after purchasing an additional 49,802 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after purchasing an additional 332,846 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the period. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.